OPR - Delayed Quote • USD FGEN Jan 2025 3.500 call (FGEN250117C00003500) Follow 1.1500 0.0000 (0.00%) At close: March 26 at 2:28 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for FGEN250117C00003500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: FGEN FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
